Editor, Ophthalmology Times
The award honors Ludwig von Sallmann, MD, a “distinguished international ophthalmologist and ophthalmic investigator whose contributions greatly increased the basic and clinical understanding of vision and ophthalmology.”
24-week topline data from the phase 2b ASPIRE study in diabetic macular edema (DME) are expected to be released in Q1 of 2025.
A survey conducted by the Preservative Freedom Coalition, asked 558 patients with glaucoma or ocular hypertension how they felt about their treatments, the future of their eye health, trust in their doctors and more.
Tarcocimab is an investigational anti-VEGF therapy built on Kodiak's proprietary antibody biopolymer conjugate (ABC) platform.
Urcosmid is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, typically found on immune cells of the eye responsible for the inflammatory response.
4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection.
ENCELTO is the first and only FDA-approved treatment for MacTel.
ENCELTO is the first and only FDA-approved treatment for MacTel.
At the EnVision Summit 2025, medical students were given awards for best poster presentation. In exclusive interviews, they spoke with Ophthalmology Times about their award-winning posters and research.
At the EnVision Summit 2025 in San Juan, Puerto Rico, Poonam Misra, MD, and Alcina Lidder, MD, gave advice on managing glaucoma in patients with other ocular co-morbidities such as myopia and those who have undergone corneal transplantation.
Cortrophin Gel is a prescription medicine that is injected subcutaneously or intramuscularly indicated for severe acute and chronic allergic and inflammatory conditions affecting the eye.
Ixo-vec utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette and is designed to be administered as a one-time intravitreal injection.
At the Envision Summit 2025 in San Juan, Puerto Rico, Amy Zhang, MD, discussed the importance of ergonomics in the operating room.
At the EnVision Summit 2025 in San Juan, Puerto Rico, Tania Tai, Lucy Shen, and Shivani Kamat all gave insight into complications they have seen while performing glaucoma surgery.
If approved, the drug will be branded as LYTENAVA.
At the Envision Summit 2025 in San Juan, Puerto Rico, Sara Wester, MD, discussed the Women Leaders in Eye Health session at the conference and the donation from Orbis that supported the session.
Bonnie Henderson, MD, founder and program director of the EnVision Summit, talked with Ophthalmology Times about the evolution of the conference and how it brings optometrists and ophthalmologists together to learn, discuss shared problems, and facilitate co-management in a family-friendly environment.
At the Envision Summit 2025 in San Juan, Puerto Rico, Kristen Nwanyanwu, MD, MBA, MHS, joined by her children, discussed her talk on eradicating TRD and the family-friendly environment of the conference.
A PDUFA date has been set for October 20, 2025. If approved, Epoxia will be the first epi-on corneal crosslinking on the market.
At the Envision Summit 2025 in San Juan, Puerto Rico, retina program chairs Geeta Lalwani, MD, and Majda Hadziahmetovic, MD, discussed Hadziahmetovic's presentation on deep learning models of neovascular AMD as well as their time at the conference.
At the Envision Summit 2025 in San Juan, Puerto Rico, Mike Farkas, MD, discussed gene therapy research for retinal degenerations that sidetracks the current "status quo" therapies of AAV-based replacement and CRISPR-Cas9 genome editing.
At the Envision Summit 2025 in San Juan, Puerto Rico, Kelly Donovan, MD, talked about her graduate research on the earliest phase of diabetic retinopathy, and trying to understand how hyperglycemia translates into disease.
At the Envision Summit 2025 in San Juan, Puerto Rico, Oleg Alekseev, MD, PhD, talked about difficulties in diagnosing inherited retinal degenerations due to mutations in over 300 different genes.
At the Envision Summit 2025 in San Juan, Puerto Rico, Ollya Fromal, MD, gave advice on how retina specialists can manage add-ons in their busy retina clinics.
At the Envision Summit 2025 in San Juan, Puerto Rico, Giulia Corradetti, MD discussed AI applications in the identification and prediction of OCT structural biomarkers in intermediate AMD.
SightScore is a saliva test that looks at millions of genetic variants in the patient’s genome to create a personalized polygenic risk score for glaucoma.
At the Envision Summit 2025 in San Juan, Puerto Rico, Sharon Fekrat, MD, FACS, FASRS talked about multi-modal retinal and choroidal imaging to diagnose and identify neurodegenerative diseases using machine learning.
At the Envision Summit 2025 in San Juan, Puerto Rico, Rachel Simpson, MD, talked about new developments in glaucoma treatment and really how to tailor glaucoma treatment to the patient.
At the Envision Summit 2025 in San Juan, Puerto Rico, Angela Zhu, MD, offered advice on cataract surgery for all ages, focusing on pediatrics.
AVT06 is Alvotech’s proposed biosimilar to Eylea (aflibercept) 2mg.
